Recent Finacing
Recent Raise
Phialogics develops genetically engineered monospecific IgV biologics, advancing preclinical autoimmune therapies designed for inflamed‑tissue and disease‑cell selectivity, based in Basel and Heidelberg.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor